AVILA THERAPEUTICS INC has a total of 111 patent applications. Its first patent ever was published in 2008. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are JOYANT PHARMACEUTICALS INC, ASTEX TECHNOLOGY LTD and HEPTARES THERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 17 | |
#2 | WIPO (World Intellectual Property Organization) | 17 | |
#3 | Canada | 11 | |
#4 | Mexico | 11 | |
#5 | Brazil | 9 | |
#6 | Republic of Korea | 8 | |
#7 | Taiwan | 8 | |
#8 | EPO (European Patent Office) | 7 | |
#9 | Singapore | 5 | |
#10 | Israel | 4 | |
#11 | United States | 4 | |
#12 | New Zealand | 3 | |
#13 | Argentina | 2 | |
#14 | Hong Kong | 2 | |
#15 | India | 1 | |
#16 | Japan | 1 | |
#17 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Computer technology | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Microorganisms | |
#5 | Peptides | |
#6 | Computational chemistry | |
#7 | Measuring microorganism processes | |
#8 | Enzymes | |
#9 | Bioinformatics | |
#10 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Singh Juswinder | 84 |
#2 | Niu Deqiang | 67 |
#3 | Kluge Arthur F | 63 |
#4 | Qiao Lixin | 57 |
#5 | Petter Russell C | 54 |
#6 | Ghosh Shomir | 34 |
#7 | Zhu Zhendong | 22 |
#8 | Tester Richland Wayne | 21 |
#9 | Mazdiyasni Hormoz | 21 |
#10 | Petter Russell | 21 |
Publication | Filing date | Title |
---|---|---|
CN103501610A | Pi3 kinase inhibitors and uses thereof | |
WO2012064706A1 | Mutant-selective egfr inhibitors and uses thereof | |
CN103269704A | Heterocyclic compounds and uses thereof | |
CN103096716A | Besylate salt of a BTK inhibitor | |
CA2785738A1 | Ligand-directed covalent modification of protein | |
KR20120063515A | Pi3 kinase inhibitors and uses thereof | |
WO2011002807A1 | Hcv protease inhibitors and uses thereof | |
CA2735937A1 | Algorithm for designing irreversible inhibitors | |
US2010016296A1 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | |
BRPI0821790A2 | Hcv protease inhibitors and uses thereof | |
NZ586232A | HCV protease inhibitors comprising a functionalised proline derivative | |
CA2702674A1 | Heteroaryl compounds and uses thereof | |
TW200908983A | Heterocyclic compounds and uses thereof |